Seres Therapeutics (MCRB) Reports Q3 EPS of $0.72
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021 7:00 AM ESTEnrollment completed in SER-109 recurrent C. difficile infection open-label study Â
Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Biologics License Application (BLA) filing in mid-2022
Collaboration with Bacthera A.G., a global leader in biopharmaceutical product manufacturing, expands existing capabilities for commercial product supply
SER-109 expanded access program initiated for adults with recurrent C. difficile infection Â
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS... More
